Capacity of neutrophils and monocytes from human immunodeficiency virus-infected patients and healthy controls to inhibit growth of Mycobacterium bovis

Journal of Laboratory and Clinical Medicine

Volumn 141, Issue 5, 2003, Pages 330-334

  Kaul, Daniel ^a   Coffey, Michael J ^a   Phare, Susan M ^a   Kazanjian, Powel H ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; COTRIMOXAZOLE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INDINAVIR; INTERLEUKIN 2; INTERLEUKIN 8; LOPINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; BACTERICIDAL ACTIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; MONOCYTE; MYCOBACTERIUM BOVIS; NEUTROPHIL; NONHUMAN; PHAGOCYTE; PNEUMOCYSTIS PNEUMONIA;

EID: 0037613786     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(03)00006-4     Document Type: Article

References (20)

1. Bermudez LE, Young LS. Recombinant granulocyte-macrophage colony-stimulating factor activates human macrophages to inhibit growth or kill Mycobacterium avium complex. J Leukoc Biol 1990;48:67-73.
2. Newman GW, Guarnaccia JR, Remold HG, Kazanjian PH. Cytokines enhance neutrophils from human immunodeficiency virus-negative donors and AIDS patients to inhibit the growth of Mycobacterium avium in vitro. Infect Dis 1997;175:891-900.
3. Baldwin GC, Gasson JC, Quan SG, Fleischmann J, Weisbart R, Oette D, et al. Granulocyte-macrophage colony-stimulating factor enhances neutrophil function in acquired immunodeficiency syndrome patients. Proc Natl Acad Sci U S A 1988;85:2763-2766.
4. Bermudez LE, Martinelli J, Petrofsky M, Kolonoski P, Young LS. Recombinant granulocyte-macrophage colony-stimulating factor enhances the effects of antibiotics against Mycobacterium avium complex infection in the beige mouse model. J Infect Dis 1994;169:575-580.
5. Roilides E, Mertins S, Eddy J, Walsh TJ, Pizzo PA, Rubin M. Impairment of neutrophil chemotactic and bactericidal function in children infected with human immunodeficiency virus type I and partial reversal after in vitro exposure to granulocyte-macrophage colony-stimulating factor. J Pediatr 1990;117:531-40.
6. Prince HE, Moody DJ, Shubin BI, Fahey JL. Defective monocyte function in acquired immune deficiency syndrome (AIDS): evidence from a monocyte-dependent T-cell proliferative system. J Clin Immunol 1985;5:21-5.
7. Pitrak DL, Bak PM, DeMarais P, Novak RM, Andersen BR. Depressed neutrophil superoxide production in human immunodeficiency virus infection. J Infect Dis 1993;167:1406-10.
8. Pitrak DL, Sutton SH, Tsai HC, Mullane KM, Pau AK. Reversal of accelerated neutrophil apoptosis and restoration of respiratory burst activity with r-metHuG-CSF (Filgrastim) therapy in patients with AIDS. AIDS 1999;13:427-9.
9. Coffey MJ, Phare SM, George S, Peters-Golden M, Kazanjian PH. Granulocyte colony-stimulating factor administration to HIV-infected subjects augments reduced leukotriene synthesis and anticryptococcal activity in neutrophils. J Clin Invest 1998;102:663-70.
10. Denis M, Ghadirian E. Granulocyte-macrophage colony stimulating factor restricts gowth of tubercle bacilli in human macrophages. Immunol Lett 1990;24:203-6.
11. George S, Coffey M, Cinti S, Collins J, Brown M, Kazanjian P. Neutrophils from AIDS patients treated with granulocyte colony-stimulating factor demonstrate enhanced killing of Mycobacterium avium. J Infect Dis 1998;178:1530-3.
12. Cinti S, Coffey M, Sullivan A, Kazanjian P. Killing of Mycobacterium avium by neutrophils and monocytes from AIDS patients treated with recombinant granulocyte-macrophage colony-stimulating factor. J Infect Dis 1999;180:229-33.
13. Moreno S, Miralles P, Diaz MD, Baraia J, Padilla B, Berenguer J, et al. Isoniazid preventive therapy in human immunodeficiency virus-infected persons: long-term effect on development of tuberculosis and survival. Arch Intern Med 1997;157:1729-1734.
14. Smith PD, Ohura K, Masur H, Lane HC, Fauci AS, Wahl SM. Monocyte function in the acquired immunodeficiency syndrome: defective chemotaxis. J Clin Invest 1984;74:2121-128.
15. Coffey M, Phare S, Cinti S, Peters-Golden M, Kazanjian P. Granulocyte-macrophage colony stimulating factor upregulates reduced 5-lipoxygenase metabolism in peripheral blood monocyte and neutrophils in AIDS. Blood 1999;94:3897-905.
16. Prince HE, Moody DJ, Shubin BI, Fahey JL. Defective monocyte function in acquired immunodeficiency syndrome (AIDS): evidence from a monocyte-dependent T-cell proliferative system. J Clin Immunol 1985;5:21-5.
17. Kemper CA, Bermudez LE, Deresinski SC. Immunomodulatory treatment of Mycobacterium avium complex bacteremia in patients with AIDS by use of recombinant granulocyte-macrophage colony-stimulating factor. J Infect Dis 1998;177:914-20.
18. Bonay M, Bouchonnet F, Pelicic V, Lagier B, Grandsaigne M, Lecossier D, et al. Effect of stimulation of human macrophages on intracellular survival of Mycobacterium boris bacillus Calmette-Guerin: evaluation with a mycobacterial reporter strain. Am J Respir Crit Care Med 1999;159:1629-37.
19. Denis M, Cormier Y, Fournier M, Tardif J, Laviolette M. Tumor necrosis factor and granulocyte-macrophage colony-stimulating factor stimulate human macrophages to restrict growth of virulent Mycobacterium avium and to kill avirulent M avium: killing effector mechanism depends on the generation of reactive nitrogen intermediates. J Leukoc Biol 1991;49:380-7.
20. Scadden D. Cytokine use in the management of HIV disease. J Acquit Immune Defic Syndr Hum Retroviral 1997;16(suppl 1): S1-S12.